AustinPx + Microsize =
Faster Commercial KinetiSol Potential
Joining Forces to Advance ASD Technologies
Sustainability. Scalability. Performance.
A Partnership That Strengthens Commercialization Options for AustinPx’s Clients.
Unlock the potential of furthering your small molecule drug candidate with revolutionary KinetiSolTM Technology. AustinPx, a contract development and manufacturing organization (CDMO), and Microsize, a CDMO specializing in micronization and particle size control, have joined forces to interrupt the amorphous solid dispersion industry.
This collaboration is originated to accelerate your project with the power of AustinPx’s groundbreaking KinetiSol Technology platform. With this partnership, clients can now manufacture their late-phase clinical and commercial KinetiSol project at Microsize’s FDA-registered cGMP manufacturing facility in Quakertown, PA.
KinetiSol Technology is at the forefront of innovation, utilizing frictional and shear energies to generate amorphous solid dispersions (ASDs) in seconds, without the use of solvents. With a higher throughput manufacturing technology, this technology allows for higher exposure at lower doses and an improved downstream processability. These features of the KinetiSol Technology allow for better sustainability, better scalability, and better performance.
To talk to one of our business development directors about developing your next drug candidate utilizing AustinPx’s KinetiSol Technology, please contact us via the form below.